Cannabis and hemp plants include more than 500 special compounds which includes cannabinoids, terpenoids, flavonoids, and fatty acids. Terpenoids are the aromatic compounds that give cannabis strains their distinct smells. Cannabinoids such as cannabidiol (CBD) and tetrahydrocannabinol (THC) are some of the most common and researched therapeutic compounds, but other minor cannabinoids are increasing in prominence – which includes cannabidivarin.
Researchers have identified more than 100 cannabinoids in cannabis and hemp plants. 1 of these cannabinoids, cannabidivarin (CBDV), is displaying promising final results in preliminary research on nausea, seizures, inflammation, muscle function, and cognitive troubles. Although CBDV is far from becoming a household name like CBD, right here are a couple of items you need to know about this non-intoxicating cannabinoid.
What is CBDV?
CBDV shares numerous chemical traits and effects with CBD. For instance, CBDV is a non-psychotropic compound that will not lead to customers to really feel the signature higher of marijuana. On top of that, CBDV investigation has shown that it can function to decrease seizures, nausea, inflammation, and discomfort, just like CBD.
CBDV was found in 1969 by researchers in the Netherlands. They identified the compound as a CBD homologue, which indicates it has a comparable structure to CBD. CBDV and CBD each have 30 stereoisomers and 7 double bond isomers, but 1 side chain is shortened by two methyl groups.
You will not discover any CBDV items at any dispensary, but some strains have been shown to include additional CBDV than other people. Study has identified that CBDV is usually identified in C. indica landrace strains from Asia and Africa, particularly from the following nations:
- South Africa
Apart from indica landrace strains sourced from Asia and Africa, greater-than-typical CBDV levels have been identified in strains that are low in THC and strains that are higher in CBD.
The present cannabis industry caters to buyers looking for THC-wealthy cultivars. Thankfully, buyers, researchers, and suppliers are increasing sensible to other minor cannabinoids such as CBDV, THCV, and THCA that have healthcare applications.
CBDV’s effects have only been identified and assessed in a clinical investigation setting. Initial investigation on CBDV beginning in 2012 utilised animal models. Preceding trials confirmed that CBDV is productive for a selection of healthcare situations. As researchers continue to study CBDV, they are getting that this compound has numerous comparable therapeutic effects to CBD. For now, CBDV has been shown to have substantial anticonvulsant, anti-inflammatory, analgesic, antiemetic, and anti-epileptic traits.
A 2012 study tested the anticonvulsant effects of CBDV in vitro and in in vivo with mice and rats. Researchers concluded that “these final results indicate that CBDV is an productive anticonvulsant in a broad variety of seizure models. Also, it did not drastically influence typical motor function, and for that reason, merits additional investigation as a novel anti-epileptic in chronic epilepsy models.”
In 2013, an additional group of researchers expanded on the initial 2012 study by examining modifications to epilepsy-associated gene expression following administering CBDV to epilepsy models. Soon after a chemical convulsant remedy, animal models have been provided CBDV (400 mg/kg, p.o.). Researchers uncovered “molecular proof that straight supports behavioral proof that CBDV exerts substantial anticonvulsant effects through oral and other routes of administration.”
Yet another study in 2013 tested the effects of THCV and CBDV on nausea on rats. Inverse agonists of the CB1 cell receptor market nausea, whilst cannabinoid agonists suppress the characteristic gaping reaction displayed by rats, which are incapable of vomiting. Researchers concluded that “neither THCV or CBDV made a behavioral profile characteristic of CB1 receptor inverse agonists. As nicely, these compounds may possibly have therapeutic prospective in minimizing nausea.”
Study in 2018 tested the effects of CBDV on mouse models with Rett syndrome, a uncommon genetic neurological and developmental disorder that disproportionately impacts girls’ motor capabilities and speech. Other symptoms of Rett syndrome consist of seizures and muscle spasticity. The study’s principal findings consist of:
- CBDV enhanced the basic well being of the animal models
- CBDV rescued the deficit in sociability of the animal models
- CBDV enhanced motor coordination of the animal models
- CBDV normalized brain weight of the animal models
- GPR55 levels elevated in hippocampus of the animal models
A study published in the British Journal of Pharmacology in 2019 on CBDV and Duchenne muscular dystrophy (DMD) identified that CBDV could advantage sufferers with DMD. DMD symptoms consist of muscle weakness and harm, inflammation, skeletal harm such as scoliosis, vision troubles, and additional. CBDV was shown to decrease inflammation and strengthen muscular function and locomotion.
At present, a study is underway on the effects of CBDV in youngsters with autism spectrum disorder (ASD) and intractable epilepsy. The double-blind randomized placebo-controlled study will treat 28 sufferers amongst the ages of five and 18. Researchers are hopeful that CBDV could alleviate some of the symptoms related with ASD which includes repetitive behavioral troubles, cognitive troubles, and communication troubles.
GW Pharmaceuticals developed the 1st FDA-authorized CBD-primarily based medication known as Epidiolex for serious types of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome. At present, GW Pharmaceuticals is producing a CBDV-primarily based drug recognized as GPW42006 to alleviate temporal lobe seizures.
In a press release, Justin Gover, GW’s Chief Executive Officer, stated that “whilst the main concentrate of GW’s epilepsy investigation system remains on Epidiolex in pediatric epilepsy, we think that CBDV may possibly give an added remedy benefit in this therapeutic location in the medium and longer term.”
CBDV, as a newly researched cannabinoid, has shown massive healthcare prospective for a selection of symptoms which includes seizures, nausea, muscle discomfort, and additional. CBDV’s non-intoxicating properties are relevant for sufferers that do not demand or want the psychotropic effects of THC. It may possibly be a whilst till CBDV medication is produced additional accessible, but present investigation is creating the case for introducing CBDV into contemporary medicine.